SCT Completes the 90 Day Endpoint Period for the Last Patient Enrolled in the Modified REGENESIS Phase IIb Stroke Trial

News   Apr 27, 2010

 
SCT Completes the 90 Day Endpoint Period for the Last Patient Enrolled in the Modified REGENESIS Phase IIb Stroke Trial
 
 
 

RELATED ARTICLES

Patent Plausability Case Sees BIA Intervention

News

The UK Bioindustry Association (BIA) will intervene in a court case which could have huge ramifications for UK bioscience.

READ MORE

PPD and Quotient Sciences Form Innovative Partnership to Accelerate Pediatric Drug Development

News

Will shorten timelines, reduce costs and simplify contracting process in pediatric programs.

READ MORE

New Cell Therapy for Diabetes Being Tested

News

The University of British Columbia and Vancouver Coastal Health are testing a possible diabetes cure that replaces a person’s damaged pancreatic cells with new ones grown in the lab.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE